Abstract
Lack of reimbursement for genomic testing in rare diseases is recognized as one of the principal barriers to wider implementation within healthcare systems [1]. Multiple studies have provided evidence for diagnostic and clinical utility and for the cost-effectiveness of genomic testing in rare diseases, leading to testing being funded across a range of public and private healthcare systems worldwide [2].
Original language | English |
---|---|
Pages (from-to) | 977-979 |
Number of pages | 3 |
Journal | European Journal of Human Genetics |
Volume | 31 |
Issue number | 9 |
Early online date | 3 Jul 2023 |
DOIs |
|
Publication status | Published - Sept 2023 |
Externally published | Yes |
Keywords
- economics
- health care
- health care economics
- health policy